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Abstract Background: The main treatment for phenylketon-
uria (PKU) is a low phenylalanine (Phe) diet, phenylalanine-
free protein substitute and low-protein special foods. This
study describes dietary composition and nutritional status in
late-diagnosed adult patients adhering to a PKU diet.
Methods: Nineteen patients, followed at Oslo University
Hospital in Norway, participated; median age was 48 years
(range 26–66). Subjects were mild to severely mentally
retarded. Food intake, clinical data and blood analyses
relevant for nutritional status were assessed.
Results: Median energy intake was 2,091 kcal/day (range
1,537–3,277 kcal/day). Carbohydrates constituted 59%
(range 53–70%) of the total energy, including 15% from
added sugar; 26% was from fat. The total protein intake was
1.02 g/kg/day (range 0.32–1.36 g/kg/day), including
0.74 g/kg/day (range 0.13–1.07 g/kg/day) from protein
substitutes. Median dietary Phe intake was 746 mg/day
(range 370–1,370 mg/day). Median serum Phe was
542 mmol/L (range 146–1,310 mg/day). Fortified protein
substitutes supplied the main source of micronutrients. Iron
intake was 39.5 mg/day (range 24.6–57 mg/day), exceeding
the upper safe intake level. Intake of folate and folic acid,
calculated as dietary folate equivalents, was 1,370 mg/day
(range 347–1744 mg/day), and resulted in high blood folate
concentrations. Median intake of vitamin B12 was 7.0 mg/day
(range 0.9–15.1 mg/day).
Conclusions: The diet supplied adequate protein and
energy. Fortification of the protein substitutes resulted in
excess intake of micronutrients. The protein substitutes may
require adjustment to meet nutritional recommendations for
adults with PKU.
Introduction
In Phenylketonuria (PKU; OMIM 261600), the conversion
of phenylalanine (Phe) to tyrosine is restrained or blocked,
due to impaired activity of the enzyme phenylalanine
hydroxylase (PAH; EC 1.14.16.1) in the liver (Scriver
et al. 2011). With the newborn screening programme,
dietary treatment is usually started in the first days of life
to avoid brain damage. The Norwegian national screening
programme was instituted around 1970. Patients born prior
to this date were usually diagnosed late and developed
various degrees of brain damage. It has been documented
that dietary treatment started on clinical indications, during
childhood or in adult years, can alleviate neurological and
behavioural symptoms and signs also in late diagnosed
patients (Yannicelli and Ryan 1995; Baumeister and
Baumeister 1998; Fitzgerald et al. 2000; Lee et al. 2009).
In Norway, late diagnosed adults with PKU are offered
dietary treatment on a permanent basis if they experience
positive effects on neurological and behavioural symptoms
during a trial period, usually lasting 3 to 6 months.
The main treatment for PKU is a low phenylalanine diet,
supplemented with a Phe-free protein substitute, vitamins
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and minerals. The aim of the diet is to reduce the level of
phenylalanine in the blood and brain. Small amounts of
protein from natural food products provide the essential
amino acid phenylalanine. The amount of Phe tolerated and
protein substitute needed vary according to the rest activity
in the PAH enzyme. The amount of dietary Phe is
determined by regular monitoring of Phe levels in the
blood (Yi and Singh 2008; Poustie and Wildgoose 2010).
To meet energy requirements, specially manufactured low
protein foods such as bread, pasta and biscuits, and natural
foods low in phenylalanine such as fruits, vegetables, sugar
and butter, are also used.
There is little documentation regarding the nutritional
consequences for adults who follow a PKU diet over years.
Hence the objectives of this study were to report the
nutrient intake of late-treated adults with PKU and describe
dietary effects on nutritional status. We wished to investi-
gate as to whether the diet used on a daily basis conformed
to nutritional recommendations and medical treatment
goals.
Methods
This was an observational cross-sectional study. Food intake
was registered for 4 days, serum Phe levels and several blood
biochemical parameters, relevant for assessing nutritional
status were evaluated. The study was organised in connection
with annual outpatient follow-up.
Subjects
The national PKU centre at Oslo University Hospital,
Norway, invited 27 late-treated adult patients to participate
in the study. All had adhered to diet for the last 12 months or
longer. Consent was received from 21 subjects. Two patients
withdrew before the study started, due to intercurrent illness
and inability to record food intake. Nineteen late-treated
subjects were recruited, 7 males and 12 females with a
median age of 48 years (range 26–66 years). The median age
at diagnosis was 3 years (range 6 months to 43 years), and
median age at diet start was 27 years (range 6 months to
47 years). Subjects had bodyweight comparable to the
general population in Norway; BMI showed a median 28
(range 20.2–38.5), four had BMI above 30. Before dietary
treatment was instituted, participants had amedian serum Phe
of 1,541 mMol/L (range 1,131–2,468 mMol/L). All partic-
ipants were ethnic Norwegians.
Subjects and carers received written and verbal informa-
tion; all communication was undertaken by the first author.
Twelve subjects, six male, six female, with a median age of
49 years (range 36–66 years) suffered severe cognitive
disability and could not give informed consent. These 12
subjects lived in small, staffed care homes, and professional
carers acted as informants and recorded the subjects’ food
intake. The remaining seven participants, one male, and six
female, median age 42 years (range 26–51 years), had
milder cognitive disabilities and were able to give informed
consent. These subjects lived by themselves or with their
parents and managed the diet with no, or limited, assistance
from the community. These seven plus one of the severely
disabled patients visited Oslo University Hospital for
annual outpatient control, information on the study and
venous blood tests. The remaining 11 participants were
unable to visit the hospital, due to mental and physical
disability and long distance to the hospital. Instead, the first
author visited the care homes, to obtain data and give
information on food recording and blood tests.
The Regional Committee for Medical Research Ethics
and the Commission for Privacy Protection at Oslo
University Hospital approved the study. Handling of blood
samples was according to provisions in the Norwegian
Biobank Act.
Food Recording
The patients or their carers kept a 4 day prospective food
diary. Food intake was recorded from Wednesday to
Saturday, or Sunday to Wednesday. The patients were
encouraged to follow their ordinary diet during food
recording. Foods were weighed on digital scales with 1 g
increments and drinks were measured in decilitres. The
diaries, personal recipes and wrapping paper for special
products were returned by mail.
The recordings were analysed using a Norwegian
commercial nutrient calculation programme “Mat pa data
4a”, based on the official Norwegian table of food
composition (Rimestad et al. 2001). Data for the protein
substitutes and the low-protein food products were added to
the database. Phenylalanine in food was calculated as 5% of
the protein content or based on analysis of amino acid
distribution (Weetch and MacDonald 2006). Vitamin B12
content was calculated manually as it was not included in
the software programme. To account for different bioavail-
ability in folate and folic acid, intake of this vitamin was
calculated as Dietary folate equivalents (DFE) (Suitor and
Bailey 2000). The Nordic Nutrition Recommendations
were used to compare intake with recommendations and
upper intake levels (Nordic Council of Ministers 2004). All
participants received individual dietary advice after the
study.
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Blood Sampling and Analyses
Blood tests were taken the day before or during the period
of food recording and after overnight fasting. For all
subjects, routine tests for serum Phe were obtained by
finger pricking. These were subsequently analysed by the
Neonatal Screening Laboratory at Oslo University Hospital.
Phe in serum was determined fluorometrically, by a method
described by M.W. McCaman (McCaman and Robins
1962). Subjects had their serum Phe levels analysed
routinely, four to ten times a year.
Venous blood samples were analysed at the Department
of Medical Biochemistry at Oslo University Hospital.
Analyses were done routinely on arrival at the laboratory
and according to standard procedures: The following
equipment was used for blood analysis: Amino acid profiles
in serum: Amino Acid Analyser Biochrom 30, Biochrom
LTD, Cambridge, UK. Serum iron analyses: Modular P800
Roche Diagnostics, Basel, Switzerland. Ferritin analyses:
Modular E170 Roche Diagnostics, Basel, Switzerland.
Haemoglobin analyses: Celldyn 4000, Abbott Laboratories,
CA, USA. Folate and B12 analyses: Immulite 2000,
Siemens Medical Solutions Diagnostics, DPC Cirrus Inc.,
Instrument Systems Division, Flanders, N.J., USA.
For two subjects, all analyses, apart from serum Phe,
amino acid profiles, folate and vitamin B12, were done at
local hospital laboratories. For two other subjects, only
capillary serum Phe was obtained, as venous blood drawing
would have required general anaesthesia.
Statistics
Microsoft ® Excel 2002 SP3 was used for statistical
analyses. Because of the small number of patients involved,
only descriptive statistics such as median and range were
used.
Results
Food and Nutrient Intake
Energy according to food groups are shown in Table 1.
Intake of low-protein special foods together with protein
substitutes constituted about half the consumed energy.
Natural low-protein products like fruits, vegetables, sweets
and soft drinks constituted approximately a fifth of the
energy. The remaining energy stemmed from animal foods
and miscellaneous food products like normal bread and
cereals, edible fats and jams. The median intake of fruits
and vegetables was 326 g (range 137–1,205 g/day). Median
fibre intake was 16 g/day (range 8–38 g/day) or 1.7 g/MJ
(range 0.9–3.4 g/MJ).
The median protein intake was 1.02 g/kg/day (range
0.32–1.36 g/kg/day). One subject reported a protein intake
below the FAO/WHO recommendation of minimum
0.75 g/kg/day (Nordic Council of Ministers 2004). Natural
protein with phenylalanine constituted about a quarter of the
consumed protein. The median Phe intake was 746 mg/day
(range 370–1,370 mg/day), or 10 mg/kg/day (range
6–21 mg/kg/day). The main source of Phe was food of
animal origin.
Six subjects had a fat intake below the recommended
minimum of 25% of energy, see Table 2. Main sources of
dietary fat were margarine, oil, butter and mayonnaise,
resulting in a median intake of 20 g/day (range 5–28 g/day)
of polyunsaturated fatty acids (PUFA), according to
recommendations for all but two subjects. All subjects ate
some long-chain PUFA; 14 used commercial fish oil
concentrates or cod liver oil daily, giving 0.5 g/day to
1.0 g/day of docosahexaenoic acid (DHA) and eicosapen-
taenoic acid (EPA) combined. Most subjects also used
sandwich fillings based on mackerel or cod roe.
The amount of energy from carbohydrate was above the
recommended level for eight subjects, mainly due to a high
intake of added sugar. Only five subjects managed to
maintain the intake of added sugar below the recommended
maximum of 10% of total energy.
In order to maintain serum Phe in the therapeutic range and
to meet each patient’s individual protein requirement, the
amounts of protein substitute taken varied. The median protein
intake from protein substitute was 0.74 g/kg/day (range
0.13–1.07 g/kg/day). Five brands of protein substitute were
used, see Table 3. The protein substitutes were fat free; four of
them were fortified with minerals and vitamins. One subject
was required to take additional supplements of vitamins, trace
minerals and calcium, since the substitute used was unforti-
fied. Use of fortified protein substitutes resulted in high
intakes of most micronutrients. The highest micronutrient
intakes were observed for iron, vitamin B12 and folic acid, see
Table 1. The mean intakes of calcium, magnesium, zinc,
selenium and vitamins A, D, C and remaining B-vitamins
also exceeded recommendations. However, as intakes did not
exceed upper safe levels of intake (Nordic Council of
Ministers 2004) and blood parameters were not adversely
influenced, the results are not reported here.
The main source of folic acid was the fortified protein
substitutes, with additional small amounts from some low-
protein special products. About 85% of DFE originated
from folic acid in the protein substitutes, ranging from
174 mg/day for the subject taking Avonil to 887 mg/day for
one subject taking Lophlex. As fortification is not permitted
in Norwegian food products, the additional food did not
contain folic acid. Dietary sources of natural folate were
vegetables, fruits, and small amounts of dairy products,









































































































































































































































































































































































































































































































































































































































































































































The intake of vitamin B12 was lower than recommended
only for the subject taking Avonil. The others had intakes
according to recommendations or higher. All subjects had
an iron intake greater than the recommendation. Almost all
dietary iron originated from fortified protein substitutes and
low protein special food. The protein substitutes contrib-
uted approximately 75% of the total iron intake. Intakes
exceeded the upper intake levels of 25 mg/day for 14
subjects. The use of food containing haemic iron and
natural B12 was minimal.
Blood Tests
Median serum Phe at the time of the study was 542 mMol/L
(range 146–1,310 mMol/L). The subjects’ mean serum Phe
level during the 12 months preceding the study showed a
median of 472 mMol/L (range 352–1,143 mMol/L). Phe
levels at the time of the study and for the preceding year
had a Spearman’s rho correlation of 0.83 (p < 0.01). Other
blood tests were analysed for 13 to 17 subjects. Folate, B12,
and iron parameters are shown in Table 4. Data for renal
function, lipids, zinc, selenium and magnesium were within
normal ranges and are not reported. Neither did the serum
amino acid profiles reveal discrepancies apart from elevated
serum Phe.
Discussion
We wished to describe nutritional implications for late-
diagnosed adults who had followed a Phe restricted diet for
at least 1 year preceding the study. PKU is a rare disease,
and even when all eligible patients in Norway were invited,
the sample size was small. The medical ethical committee
required that the burden of participation should be minimal
for retarded subjects. Thus, only blood tests commonly
done at annual follow-up were allowed. However, all
subjects had capillary serum Phe levels analysed routinely,
and the stable Phe levels indicated that the diet was well
adhered to. Most subjects chose to maintain serum Phe
above the Norwegian treatment goal of maximum 400
mMol/L. For these adults, the optimal serum Phe level was
individually chosen and can be seen as a compromise
between the effects on patients’ emotional and behavioural
functions and their ability to adhere to and manage the diet.
The Phe levels in this study are comparable to the levels
reported in other studies for late-diagnosed patients with
PKU (Lee et al. 2009; Trefz et al. 2011) and to the levels
reported to have positive effects on early-treated adult
patients’ mood and attention (Ten Hoedt et al. 2011).
The stable serum Phe levels and the relatively high
energy intakes reported support our assumption that the food
recordings reflected patients’ habitual dietary intake. The
detailed and meticulously recorded registrations supplied
important data on how the patients chose to eat at home.
Table 2 Distribution of energy in the diet of late-treated PKU patients
Proportion of total intake (%)
Median (range) Nordic recommendations
Protein 14 (6–20) 10–20
Fat 26 (17–35) 25–35
Saturated fat 9 (5–17) ca 10
Polyunsaturated fat 7 (2–11) 5–10
Carbohydrate 59 (53–70) 50–60
Added sugar 15 (2–31) <10
Table 3 The contents of selected nutrients in the different types of protein substitutes used by late-treated PKU patients
Type of protein substitutes
XP Maxamuma Lophlex powdera PKU Expressb Avonilc Prekunilc
Number of subjects using each substitute 13 1 3 1 1
Nutrientsper 100 g of substitute
Protein equivalents (g) 30 72 60 55.8 55
Iron (mg) 23.5 19.2 21.6 16 0
Vitamin B12 (mg) 3.6 6.4 9.4 1.1 0
Folic acid (mg) 500 896 400 226 0
DFEd (mg) 850 1,523 680 384 0
a XP Maxamum and Lophlex powder by Nutricia
b PKU Express by Vitaflo International Ltd
c Avonil and Prekunil by Prekulab Ltd
d Dietary Folate Equivalents (DFE): 1 mg folic acid as a fortificant ¼ 1.7 mg DFE
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Such knowledge is of great value for dieticians and doctors
when giving dietary advice and prescribing medical food.
As reported by MacDonald et al. (2003), fruits and
vegetables can be used almost without restriction in the
PKU diet. However, several subjects in the study consumed
only small amounts of these foods, thus restricting their diet
more than necessary. Intake of fruits and vegetables was
comparable to the Norwegian mean intake, and might
reflect what patients and carers considered normal portions.
Availability and food price might also influence the use of
these foods. Fruits and vegetables were the main source of
fibre in the PKU diet. Only individuals with high intakes
managed to reach the recommended intake of 25–35 g fibre
per day. Readily available, low-cost sweets and soft drinks
were used in considerable amounts.
A high sugar intake combined with low fat content in
most low-protein special food used might increase the risk
of deficiency of essential fatty acids, and, indeed, low
intakes of PUFA in PKU diets are reported in several
studies. Most studies, like the study by Rose et al., are
performed on children (Rose et al. 2005). Mosely et al.
reported that also adults with PKU had insufficient intakes
of PUFA (Moseley et al. 2002). In contrast, our study
showed a sufficient intake of essential fatty acids, when all
PUFA were taken together. Omega-3 supplements and fish-
based bread spreads were widely used. Such products are
common in Norwegian diets, and were not viewed as
special to the PKU diet by the subjects or carers. More
knowledge about intake and requirements for long-chain
PUFA, in particular DHA status, is needed as this might
influence cognitive outcome in PKU (Yi et al. 2011). In this
study, however, only the dietary amounts of total PUFA
seem relevant as subjects started treatment late.
The food recordings and serum amino acid profiles
indicated that the subjects had a protein intake in
accordance with requirements. This indicates that a low
Phe diet supplemented with protein substitute will fulfil
protein requirements for adult PKU patients. However, the
amount of protein substitute necessary, coupled with the
high fortification levels in these products, resulted in
excessive intakes of most vitamins and trace minerals for
these adults. This was reflected in high levels of folate in
both erythrocytes and serum. Similar high folate levels
were reported by Robinson et al. who assumed the high
levels resulted from large amounts of vegetables in the
PKU diet (Robinson et al. 2000). In our study, however,
low vegetable consumption resulted in a low intake of
natural folate. Even if the subjects had doubled their
vegetable intake, the natural folate would be a minor
fraction of the folic acid intake from protein substitutes.
The intake and blood parameters reported indicate that the
amounts of folic acid in three of the protein substitutes used
are excessive for adult patients. The two subjects using
Prekunil and Avonil had intakes of folic acid and vitamin
B12 comparable to recommendations. They were the only
subjects with erythrocyte and serum folate within normal
range, see Table 4.
Natural sources of vitamin B12 are scarce in the PKU
diet and several reports show that adults with PKU risk B12
deficiency if fortified protein substitutes are not taken
(Hanley et al. 1993; Robinson et al. 2000; Hvas et al.
2006). In this study, all subjects took the substitutes as
prescribed, and the high intake of vitamin B12 in most
protein substitutes was reflected in the blood analyses, see
Table 4. Vugteveen et al. report that vitamin B12 concen-
trations in serum within reference values, do not exclude
functional vitamin B12 deficiency in PKU patients. In order
to detect this, they recommend measuring serum methyl-
malonic acid or plasma homocysteine for these patients in
the future (Vugteveen et al. 2011).
Despite a high iron intake, the blood analyses revealed
no signs of iron overload. This indicates a low absorption
of dietary iron in PKU diets. Similar lack of correlation is
reported earlier in PKU children (Arnold et al. 2001;
Acosta et al. 2004). Similar to reports by MacDonald, some
subjects in our study complained of abdominal discomfort
Table 4 Nutritional biochemical parameters of the late-treated PKU patients
Median (range) Normal range at the laboratory used
B-Haemoglobin (n ¼ 13), g/dL 13.5 (12.9–15.2) Men: 13.4–17
Women: 11.7–17
S-iron (n ¼ 15), g/L 17 (7–27) 9–34
P-Ferritin (n ¼ 16), mg/L 53 (9–257) Men: 29–383
Women: 10–167
S-Vitamin B12 (n ¼ 17), pmol/L 580 (110–1,030) 160–710
ER-folate (n ¼ 13), nmol/L 1,870 (605–3,165) 390–1,140
S-folate (n ¼ 15), nmol/L 53.0 (22.3–>54.4) 7.1–27
N number of subjects tested
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after taking the protein substitutes (MacDonald 2000). The
possibility that excessive amounts of intestinal iron and
other micronutrients contribute to these symptoms cannot
be excluded.
Fortification of protein substitutes makes the diet less
complicated and makes it easier to comply to and organise
the diet, as shown by MacDonald (2000). The protein
substitutes used in this study were recommended for older
children, adolescents and adults. Our findings raise the
question of whether a single product can meet the require-
ments for protein and micronutrients in children as well
as adults. The amounts of micronutrients in the protein
substitutes might need adjustment in order to meet vitamin
and mineral recommendations in adult PKU patients. Further
investigations, preferably in controlled studies with larger
samples of adult PKU patients are necessary. Nutrient
composition in the protein substitutes should be aimed
at improving nutrient status in all adults adhering to a
PKU diet.
In Summary
Despite methodological limitations in the present study, the
data obtained showed that late-treated adult PKU patients
manage to maintain a diet with adequate protein intake and
therapeutic serum Phe levels over time. Subjects had,
however, problems in adhering to nutritional recommenda-
tions for fruits and vegetables, added sugar and dietary
fibre. Recommended intake of essential fatty acids required
use of omega-3 supplements. Intake of folic acid, vitamin
B12 and iron was very high, due to fortification of the
protein substitutes. The food records were carefully and
accurately done, showing excess intakes of micronutrients
for all subjects using highly fortified protein substitutes. We
presume that early and continuously treated adults with
classical PKU may have similar intakes when low blood
Phe levels are maintained by diet alone. Further studies are
needed to determine if requirements for micronutrients and
omega-3 fatty acids differ in PKU patients compared to the
general population. In the meantime composition of protein
substitutes intended for adults with PKU might need
adjustment.
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